登录 注册 会员服务 联系我们

Safety and efficacy of nivolumab in the treatment of cancers: A meta-analysis of 27 prospective clinical trials

  • Published:2016-11-16 Issue:4 Volume:140 Page:948-958
  • ISSN:0020-7136
  • Container-title:International Journal of Cancer
  • language:en
  • Short-container-title:Int. J. Cancer

Author:

Tie Yan12,Ma Xuelei12,Zhu Chenjing3,Mao Ye12,Shen Kai3,Wei Xiawei4,Chen Yan4,Zheng Heng5

Affiliation:

1. State Key Laboratory of Biotherapy and Cancer Center; West China Hospital, West China Medical School Sichuan University; Chengdu China

2. Collaborative Innovation Center of Biotherapy, West China Hospital, West China Medical School Sichuan University; Chengdu China

3. West China Medical School, West China Hospital, Sichuan University; Chengdu China

4. Department of Gerontology; West China Hospital, Sichuan University; Chengdu China

5. Department of Gynaecology; West China Second Hospital, Sichuan University; Chengdu China

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference52 articles.

1. Global cancer statistics, 2012;Torre;CA Cancer J Clin,2015

2. A history of cancer chemotherapy;DeVita;Cancer Res,2008

3. Cancer immunotherapy comes of age;Mellman;Nature,2011

4. Checkpoint blockade in cancer immunotherapy;Korman;Adv Immunol,2006

5. PD-1 and its ligands in tolerance and immunity;Keir;Annu Rev Immunol,2008
同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3